BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites

Reuters

Jan 06

Jan 6 (Reuters) - Aclarion Inc ACON.O:

ACLARION ANNOUNCES FIRST PATIENT ENROLLMENTS AT TWO ADDITIONAL CLARITY TRIAL SITES AND PROVIDES GUIDANCE ON EXPECTED AVAILABILITY OF INITIAL DATA
ACLARION INC - FIRST INTERIM DATA READOUT EXPECTED IN 3Q 2026
ACLARION INC - ACLARION TARGETS FULL ENROLLMENTOF 300 PATIENTS BY MID-2027

Source text: ID:nGNX9Fnb9t

Further company coverage: ACON.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2601891509"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601891509\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601891509?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601891509","market":"fut","top_or_hot":-1,"title":"BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites </title></head><body><p><span>Jan 6 (Reuters)</span><span> - </span>Aclarion Inc <span>ACON.O</span>:</p><ul><li><p>ACLARION ANNOUNCES FIRST PATIENT ENROLLMENTS AT TWO ADDITIONAL CLARITY TRIAL SITES AND PROVIDES GUIDANCE ON EXPECTED AVAILABILITY OF INITIAL DATA</p></li><li><p>ACLARION INC - FIRST INTERIM DATA READOUT EXPECTED IN 3Q 2026</p></li><li><p>ACLARION INC - ACLARION TARGETS FULL ENROLLMENTOF 300 PATIENTS BY MID-2027</p></li></ul><p>Source text: <span>ID:nGNX9Fnb9t</span></p><p>Further company coverage: <span>ACON.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 19:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites </title></head><body><p><span>Jan 6 (Reuters)</span><span> - </span>Aclarion Inc <span>ACON.O</span>:</p><ul><li><p>ACLARION ANNOUNCES FIRST PATIENT ENROLLMENTS AT TWO ADDITIONAL CLARITY TRIAL SITES AND PROVIDES GUIDANCE ON EXPECTED AVAILABILITY OF INITIAL DATA</p></li><li><p>ACLARION INC - FIRST INTERIM DATA READOUT EXPECTED IN 3Q 2026</p></li><li><p>ACLARION INC - ACLARION TARGETS FULL ENROLLMENTOF 300 PATIENTS BY MID-2027</p></li></ul><p>Source text: <span>ID:nGNX9Fnb9t</span></p><p>Further company coverage: <span>ACON.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACON","symbol_name":"ACLARION, INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61A2:1","article_id":"2601891509","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601891509","pubTimestamp":1767699649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites Jan 6 (Reuters) - Aclarion Inc ACON.O:ACLARION ANNOUNCES FIRST PATIENT ENROLLMENTS AT TWO ADDITIONAL CLARITY TR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACON":"ACLARION, INC","BK4167":"医疗保健技术","ACONW":"Aclarion Equity Warrant Exp 1st Dec 2026 Warrant"},"translate_title":"简报-Aclarion宣布在另外两个Clarity试验点招募第一批患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACONW":0.9,"ACON":0.9},"content_text":"BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites Jan 6 (Reuters) - Aclarion Inc ACON.O:ACLARION ANNOUNCES FIRST PATIENT ENROLLMENTS AT TWO ADDITIONAL CLARITY TRIAL SITES AND PROVIDES GUIDANCE ON EXPECTED AVAILABILITY OF INITIAL DATAACLARION INC - FIRST INTERIM DATA READOUT EXPECTED IN 3Q 2026ACLARION INC - ACLARION TARGETS FULL ENROLLMENTOF 300 PATIENTS BY MID-2027Source text: ID:nGNX9Fnb9tFurther company coverage: ACON.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}